News
FDA approves clesrovimab for preventing RSV in infants
The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns, Merck announced.Merck said it plans to make the shot available for the 2025-2026 RSV season under the brand name Enflonsia.
10don MSN
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody ... to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or ...
A draft agenda for an upcoming meeting of CDC vaccine experts indicated on Wednesday that there would be no discussion about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results